GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (STU:115) » Definitions » EV-to-FCF

Abattis Bioceuticals (STU:115) EV-to-FCF : 7.46 (As of May. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Abattis Bioceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Abattis Bioceuticals's Enterprise Value is €21.60 Mil. Abattis Bioceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2019 was €2.90 Mil. Therefore, Abattis Bioceuticals's EV-to-FCF for today is 7.46.

The historical rank and industry rank for Abattis Bioceuticals's EV-to-FCF or its related term are showing as below:

STU:115's EV-to-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.08
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Abattis Bioceuticals's stock price is €0.00. Abattis Bioceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was €0.000. Therefore, Abattis Bioceuticals's PE Ratio for today is N/A.


Abattis Bioceuticals EV-to-FCF Historical Data

The historical data trend for Abattis Bioceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals EV-to-FCF Chart

Abattis Bioceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abattis Bioceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abattis Bioceuticals's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abattis Bioceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's EV-to-FCF falls into.



Abattis Bioceuticals EV-to-FCF Calculation

Abattis Bioceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=21.601/2.895
=7.46

Abattis Bioceuticals's current Enterprise Value is €21.60 Mil.
Abattis Bioceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abattis Bioceuticals  (STU:115) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Abattis Bioceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00/0.000
=N/A

Abattis Bioceuticals's share price for today is €0.00.
Abattis Bioceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Abattis Bioceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Abattis Bioceuticals (STU:115) Business Description

Traded in Other Exchanges
N/A
Address
1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6
Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.

Abattis Bioceuticals (STU:115) Headlines

No Headlines